Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Retires Convertible Debt

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – CombiMatrix today said that it has fully repaid its secured convertible debenture held by YA Global Investments.

The debenture had an original principal amount of $10 million and was sold to the investment firm in July 2008. The note was due in July of this year, or within four months after CombiMatrix receives payment from National Union Fire Insurance Company in accordance with a $35.7 million judgment issued by the United States District Court for the Central District of California.

In late January, CombiMatrix said that it had reached a settlement agreement with National Union, under which it will receive $25 million.

CombiMatrix said that as a result of retiring the note, it also has retired the potentially dilutive reserve of approximately 1.1 million shares of common stock that could have been issued in the conversion.

"Retiring this debt strengthens our overall financial position and better positions CombiMatrix for future growth as well as attaining our strategic objectives," CombiMatrix CFO and Treasurer Scott Burell said in a statement.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.